Achieve Life Sciences, Inc. (ACHV) Financials
ACHV Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 190.4 million | 205.1 million |
| March 31, 2026 | 33.1 million | 22.4 million |
| Dec. 31, 2025 | 41.8 million | 20.3 million |
| Sept. 30, 2025 | 52.0 million | 18.4 million |
ACHV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -10.8 million | 7.0 million |
| March 31, 2026 | -6.9 million | -685000 |
| Dec. 31, 2025 | -18.0 million | 1.3 million |
| Sept. 30, 2025 | -11.3 million | 2.3 million |
ACHV Net Income
No data available :(
ACHV Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 187.3 million | 7.5 million | - |
| March 31, 2026 | 29.3 million | 9.3 million | 51000 |
| Dec. 31, 2025 | 36.4 million | 11.2 million | 61000 |
| Sept. 30, 2025 | 48.1 million | 8.7 million | 80000 |
ACHV Shares Outstanding
ACHV Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 16000 | 3.8 million | 14.6 million | - |
| March 31, 2026 | - | 3.3 million | 7.1 million | 24000 |
| Dec. 31, 2025 | 3000 | 3.9 million | 10.9 million | - |
| Sept. 30, 2025 | - | 5.3 million | 9.4 million | - |
ACHV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 57000 |
| Dec. 31, 2025 | - | 57000 |
| Sept. 30, 2025 | - | 54000 |
ACHV
Price: $7.59
52 week price:
Earnings Per Share: -1.66 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: Canada
Volume: 92500
Ebitda: -8.6 millionMarket Capitalization: 695.0 million